Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rick Chatwell (NPI 1841260478)

Field	Value
Entity Type	Individual
Organization	Rick Chatwell
Address	3901 Pine Lake Rd
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Rheumatology Physician
NPI Enumerated	January 25, 2006

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

Provider billing is effectively single-payer Medicare: lifetime Medicare revenue is $3.5M and there is no Medicaid billing on file, so Medicaid does not contribute to this provider’s revenue mix. This concentration means payer analysis and contract negotiation should focus on Medicare reimbursement and utilization patterns.

Revenue is highly concentrated in a few biologic drug codes: the precomputed top three Medicare codes account for 53.9% of total Medicare revenue, led by J0129 at $777.8K (22.3%), J0717 at $716.8K (20.5%), and J0897 at $387.7K (11.1%). These three drug/infusion codes together drive the majority of the provider’s Medicare dollars, indicating drug administration is the primary revenue stream.

Code mix and descriptions indicate an infusion- and biologic-focused rheumatology practice: the top codes are largely injectable biologics (J0129 abatacept, J0717 certolizumab pegol, J0897 denosumab) and additional biologics appear across the list (J3262, J9312, J1745, J1602). The presence of multiple IV/subcutaneous biologics plus chemotherapy administration codes suggests the provider operates an infusion-capable clinic that bills for drug supply and administration as a core service line.

Competitive standing is mixed across specific drugs: J0717 ranks #40 of 848 providers nationally (95th percentile) and is described as notably above typical national volume, and J0897 ranks #244 of 10057 providers nationally (98th percentile) and is also notably above typical national volume. By contrast, J0129 ranks #99 of 1221 providers nationally (92th percentile) and is characterized as typical, unremarkable volume, so the provider is a high-volume national participant for some biologics while more typical for others.

Several administration and evaluation codes are extreme or notable outliers versus peers: 96401 is an extreme outlier at the 99th percentile, 99205 is an extreme outlier at the 99th percentile, and 96413 is notably above typical national volume at the 96th percentile. These signals indicate unusually high volumes of parenteral/infusion administration and some high-complexity new-patient visits relative to national peers.

E&M visits and clinic-level evaluation revenue represent a small share of totals: 99214 contributes $70.9K (2.0%) of Medicare revenue and ranks #14957 of 479517 providers nationally (97th percentile), showing above-typical volume for moderate-complexity follow-up visits while still accounting for a small fraction of overall revenue compared with biologic drug codes. This supports the interpretation that drug/infusion billing, not office visits, is the dominant revenue driver.

Ancillary services and lab ordering support an infusion practice: phlebotomy 36415 ranks #891 of 86467 providers nationally (99th percentile) and lab codes such as 82565 rank #79 of 5066 providers nationally (98th percentile) and 85027 rank #195 of 7266 providers nationally (97th percentile). These high percentiles for specimen collection and common rheumatology labs indicate substantial on-site testing and monitoring accompanying infusions, though these items represent modest revenue shares.

Provider tenure is long-standing: NPI enumerated 2006-01-25 (~20 years ago), consistent with an established referral base and operational stability. Combined with the concentration in biologic administration and the high national percentiles on several infusion and administration codes, this suggests a mature practice model centered on infusion-delivered therapies for rheumatologic indications.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

61 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	22,880	$30	$777.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	179,200	$1	$716.8K
J0897	Injection, denosumab, 1 mg	21,540	$20	$387.7K
J3262	Injection, tocilizumab, 1 mg	77,000	$10	$385K
J9312	Injection, rituximab, 10 mg	5,300	$60	$339.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	7,770	$30	$202K
J1602	Injection, golimumab, 1 mg, for intravenous use	16,350	$10	$179.9K
J3111	Injection, romosozumab-aqqg, 1 mg	18,690	$10	$149.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	900	$80	$70.9K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,250	$50	$61.4K

Showing 1–10 of 61

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Rick Chatwell — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

61 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	10	8,880	$30	$476.1K
J0717	2	10	56,400	$1	$414.5K
J3262	2	10	55,060	$1	$340.9K
J9312	1	10	5,020	$60	$318.5K
J3111	4	10	28,140	$10	$291.3K
J1602	2	10	16,350	$10	$204.1K
J1745	2	40	1,770	$30	$71.8K
J0897	2	200	2,040	$20	$62.7K
96413	5	80	60	$90	$18.2K
99214	99	3,210	110	$70	$14.9K

Showing 1–10 of 61

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rick Chatwell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
William Saalfeld	NE	Acute Care Nurse Practitioner	$30.6K	$0
Karis Lange	NE	Physician Assistant	$25K	$0
Kristin Twidwell	NE	Physician Assistant	$24.2K	$0
Samone Wulf	NE	Physician Assistant	$9K	$0
Kaila Steinkuhler	NE	Physician Assistant	$1.4K	$0

Nearby Providers

Other providers in the same ZIP code as Rick Chatwell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0
Stacey Knox	NE	Hematology & Oncology Physician	$1.4M	$0

Rick Chatwell — Billing Profile & Reimbursement Data

Sign up for Rick Chatwell — Billing Profile & Reimbursement Data policy alerts

Rick Chatwell — Billing Profile & Reimbursement Data

Sign up for Rick Chatwell — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References